Business Description
Akebia Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutics for patients with kidney disease. Headquartered in Cambridge, Massachusetts, the company specializes in treatments based on hypoxia-inducible factor (HIF) biology and complement inhibition. Its commercial portfolio primarily targets complications of chronic kidney disease, such as anemia and hyperphosphatemia.
Everything on Akebia Therapeutics, Inc.
Revenue (FY2025)
$236M
YoY growth
+47.5%
Operating margin
9.9%
Direction
Expanding
Gross margin
83.3%
Net margin
-2.3%
Adrian Adams — Director (Class III), Chairperson
View full profile ↗
Michael Rogers — Director (Class III)
View full profile ↗
LeAnne M. Zumwalt — Director (Class III)
View full profile ↗
John P. Butler — Director, President and Chief Executive Officer
View full profile ↗
Ronald E. Frieson — Director (Class I)
View full profile ↗
Cynthia Smith — Director (Class I)
View full profile ↗
Philip J. Vickers, Ph.D. — Director (Class I)
View full profile ↗
Myles Wolf, M.D., M.M.Sc. — Director (Class II)
View full profile ↗
Steven C. Gilman, Ph.D. — Director (Class I) (resigned effective April 1, 2026)
View full profile ↗
Erik J. Ostrowski — Senior Vice President, Chief Financial Officer, Chief Business Officer and Treasurer
View full profile ↗
Steven K. Burke, M.D. — Senior Vice President, Chief Research & Development Officer and Medical Officer
View full profile ↗
Nicholas P. Grund — Senior Vice President, Chief Commercial Officer
View full profile ↗
Carolyn M. Rucci — Senior Vice President, Chief Legal Officer and Secretary
View full profile ↗
Share Repurchase Program
Akebia is a clinical- and commercial-stage biopharmaceutical company that has not authorized a common-stock repurchase program; the FY2025 10-K discloses no share-repurchase or buyback activity (the company has historically funded operations through equity and debt financings rather than returning capital to shareholders).
Named Competitors
AmgenJohnson & JohnsonCSL ViforRocheAstellas PharmaTeva PharmaceuticalsPfizerSanofiFresenius Medical CareArdelyx
Customer Concentration
Revenue is highly concentrated among a few dialysis organizations and distributors: in fiscal 2025, Fresenius Medical Care Rx accounted for 30%, U.S. Renal Care 29%, and DaVita, Inc. 25% of total gross revenues from Auryxia and Vafseo, and these three dialysis organizations together represented a significant percentage of gross revenue.